Cited by 394Treatment of Major DepressionNerve injury and regenerationComputational Drug Discovery Methods

Identification of a low–molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice

Open access
Cazorla, Maxime, Prémont, Joël, Mann, Andre, Girard, Nicolas, Kellendonk, Christoph, Rognan, Didier·2011·Journal of Clinical Investigation

Abstract

The neurotrophin brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin-related kinase B (TrkB) have emerged as key mediators in the pathophysiology of several mood disorders, including anxiety and depression. However, therapeutic compounds that interact with TrkB receptors have been difficult to develop. Using a combination of structure-based in silico screening and high-capacity functional assays in recombinant and neuronal cells, we identified a low-molecular weight TrkB ligand (ANA-12) that prevented activation of the receptor by BDNF with a high potency. ANA-12 showed direct and selective binding to TrkB and inhibited processes downstream of TrkB without altering TrkA and TrkC functions. KIRA-ELISA analysis demonstrated that systemic administration of ANA-12 to adult mice decreased TrkB activity in the brain without affecting neuronal survival. Mice administered ANA-12 demonstrated reduced anxiety- and depression-related behaviors on a variety of tests predictive of anxiolytic and antidepressant properties in humans. This study demonstrates that structure-based virtual screening strategy can be an efficient method for discovering potent TrkB-selective ligands that are active in vivo. We further propose that ANA-12 may be a valuable tool for studying BDNF/TrkB signaling and may constitute a lead compound for developing the next generation of therapeutic agents for the treatment of mood disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci43992

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ANA-12 is a selective partial agonist developed by Cazorla et al. using structure-based in silico screening.

    “ANA-12 is a selective partial agonist that was first developed by Carzola et al. in 2011 using a structure-based in silico screening (Cazorla et al. 2011).”

    From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Cazorla et al. 2011

    The paper identifies ANA-12 as a selective TrkB antagonist, not a partial agonist (section on structure-based virtual screening; no page available). Its account of virtual screening and its TrkB-selectivity experiments support those parts of the sentence, but directly contradict its description of ANA-12’s activity. (LLM, conf=0.92)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • BDNF stimulation increases neurite outgrowth in PC12 cells transfected with TrkB compared to non-treated cells.

    “Indeed, when PC12 cells transfected with TrkB were stimulated with BDNF for 48 h, neurite outgrowth was increased compared to the non-treated cells (Cazorla et al. 2011).”
  • ANA-12 is a low-molecular weight antagonist of TrkB that can induce anxiolytic and antidepressant properties.

    “In their study, the authors identified a low-molecular weight antagonist of TrkB that could induce anxiolytic and antidepressant properties.”
  • TrkB antagonists could induce cell death, an issue that should be addressed when considering chronic treatment regimens.

    “In spite of these interesting results, antagonists could also induce cell death, an issue that should be addressed when considering using these agents in chronic treatment regimens (Cazorla et al. 2011; Takemoto et al. 2015).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 50 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., & Rognan, D.
Affiliations
  • Inserm (FR)
  • Laboratoire d'Innovation Thérapeutique (FR)
  • Columbia University Irving Medical Center (US)
Venue
Journal of Clinical Investigation
Published
2011-05-02
Volume
121
Issue
5
Pages
1846-1857
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2087102666
Cited by
392
References
50
Citations by year
2026: 32 · 2025: 23 · 2024: 21 · 2023: 21 · 2022: 22 · 2021: 21 · 2020: 39 · 2019: 29 · 2018: 47 · 2017: 22 · 2016: 29 · 2015: 32 · 2014: 19 · 2013: 16 · 2012: 13
FWCI
12.65
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Université de Strasbourg
  • Centre National de la Recherche Scientifique
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
Keywords
TrkB receptor, brain-derived neurotrophic factor, ANA-12, anxiolytic effects, antidepressant effects, mood disorders, anxiety, depression, structure-based virtual screening, BDNF/TrkB signaling
MeSH terms
Animals, Antidepressive Agents, Anxiety, Azepines, Behavior, Animal, Benzamides, Brain, Chemistry, Pharmaceutical, Depression, Enzyme-Linked Immunosorbent Assay, Humans, Ligands, Molecular Weight, Neurons, Anti-Anxiety Agents, Drug Design, Signal Transduction, Brain-Derived Neurotrophic Factor, Mood Disorders, Receptor, trkB, Receptor, trkA, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review